The Korea Times
amn_close.png
amn_bl.png
National
  • Politics
  • Foreign Affairs
  • Multicultural Community
  • Defense
  • Environment & Animals
  • Law & Crime
  • Society
  • Health & Science
amn_bl.png
Business
  • Tech
  • Bio
  • Companies
  • World Expo 2030
amn_bl.png
Finance
  • Companies
  • Economy
  • Markets
  • Cryptocurrency
amn_bl.png
Opinion
  • Editorial
  • Columns
  • Thoughts of the Times
  • Cartoon
  • Today in History
  • Blogs
  • Tribune Service
  • Blondie & Garfield
  • Letter to the Editor
amn_bl.png
Lifestyle
  • Travel & Food
  • Trends
  • People & Events
  • Books
  • Around Town
  • Fortune Telling
amn_bl.png
Entertainment & Arts
  • K-pop
  • Films
  • Shows & Dramas
  • Music
  • Theater & Others
amn_bl.png
Sports
  • Hangzhou Asian Games
amn_bl.png
World
  • SCMP
  • Asia
amn_bl.png
Video
  • Korean Storytellers
  • POPKORN
  • Culture
  • People
  • News
amn_bl.png
Photos
  • Photo News
  • Darkroom
amn_NK.png amn_DR.png amn_LK.png amn_LE.png
  • bt_fb_on_2022.svgbt_fb_over_2022.svg
  • bt_twitter_on_2022.svgbt_twitter_over_2022.svg
  • bt_youtube_on_2022.svgbt_youtube_over_2022.svg
  • bt_instagram_on_2022.svgbt_instagram_over_2022.svg
The Korea Times
amn_close.png
amn_bl.png
National
  • Politics
  • Foreign Affairs
  • Multicultural Community
  • Defense
  • Environment & Animals
  • Law & Crime
  • Society
  • Health & Science
amn_bl.png
Business
  • Tech
  • Bio
  • Companies
  • World Expo 2030
amn_bl.png
Finance
  • Companies
  • Economy
  • Markets
  • Cryptocurrency
amn_bl.png
Opinion
  • Editorial
  • Columns
  • Thoughts of the Times
  • Cartoon
  • Today in History
  • Blogs
  • Tribune Service
  • Blondie & Garfield
  • Letter to the Editor
amn_bl.png
Lifestyle
  • Travel & Food
  • Trends
  • People & Events
  • Books
  • Around Town
  • Fortune Telling
amn_bl.png
Entertainment & Arts
  • K-pop
  • Films
  • Shows & Dramas
  • Music
  • Theater & Others
amn_bl.png
Sports
  • Hangzhou Asian Games
amn_bl.png
World
  • SCMP
  • Asia
amn_bl.png
Video
  • Korean Storytellers
  • POPKORN
  • Culture
  • People
  • News
amn_bl.png
Photos
  • Photo News
  • Darkroom
amn_NK.png amn_DR.png amn_LK.png amn_LE.png
  • bt_fb_on_2022.svgbt_fb_over_2022.svg
  • bt_twitter_on_2022.svgbt_twitter_over_2022.svg
  • bt_youtube_on_2022.svgbt_youtube_over_2022.svg
  • bt_instagram_on_2022.svgbt_instagram_over_2022.svg
  • Login
  • Register
  • Login
  • Register
  • The Korea Times
  • search
  • all menu
  • Login
  • Subscribe
  • Photos
  • Video
  • World
  • Sports
  • Opinion
  • Entertainment & Art
  • Lifestyle
  • Finance
  • Business
  • National
  • North Korea
  • 1

    BTS' Jungkook to drop 2nd solo single

  • 3

    Trailblazing nonagenarian artist honored for redefining Korean fiber art

  • 5

    Opposition leader Lee again proposes talks with President Yoon

  • 7

    BTS' Jungkook drops 2nd solo single

  • 9

    Korea fails to be included on FTSE Russell's global bond index

  • 11

    Yoon hosts Chuseok luncheon for Korean atomic bomb victims in Hiroshima

  • 13

    VIDEOBustling Chuseok: Namsan Hanok Village immerses visitors in Korea's rich traditions

  • 15

    My left arm: how right-handed shooter won Asiad medal with left hand

  • 17

    Following successful Asiad debut, swimmer Hwang Sun-woo turns eyes to bright future

  • 19

    S. Korea cruises past N. Korea in women's basketball

  • 2

    Korea wins gold in League of Legends competition; Faker tops podium

  • 4

    PHOTOSTrapped along borders

  • 6

    Pentagon's CWMD strategy document calls N. Korea 'persistent threat'

  • 8

    Are 'finfluencers' helping or harming investment community?

  • 10

    Apple, China met to discuss Beijing's crackdown on western apps: WSJ

  • 12

    Swimmer Kim Woo-min captures 3rd gold in Hangzhou

  • 14

    Second release of Fukushima wastewater to start next week

  • 16

    Builders vie for leadership in modular construction

  • 18

    S. Korea eliminates N. Korea in women's table tennis doubles

  • 20

    Korean fencers prove their unrivaled prowess in Asian Games with 6 golds

Close scrollclosebutton

Close for 24 hours

Open
  • The Korea Times
  • search
  • all menu
  • Login
  • Subscribe
  • Photos
  • Video
  • World
  • Sports
  • Opinion
  • Entertainment & Art
  • Lifestyle
  • Finance
  • Business
  • National
  • North Korea
Business
  • Tech
  • Bio
  • Companies
  • World Expo 2030
Sun, October 1, 2023 | 00:43
Retail & Food
Hanmi goes beyond pharmaceuticals
Posted : 2020-01-01 16:07
Updated : 2020-01-01 16:07
Nam Hyun-woo
Print PreviewPrint Preview
Font Size UpFont Size Up
Font Size DownFont Size Down
  • facebook
  • twitter
  • kakaolink
  • whatsapp
  • reddit
  • mailto
  • link
Hanmi Pharmaceutical headquarters in Songpa-gu, Seoul / Courtesy of Hanmi Pharmaceutical
Hanmi Pharmaceutical headquarters in Songpa-gu, Seoul / Courtesy of Hanmi Pharmaceutical
Pharmaceutical firm looks to offer 'omnibus life care' to patients

By Nam Hyun-woo

Hanmi Pharmaceutical headquarters in Songpa-gu, Seoul / Courtesy of Hanmi Pharmaceutical
Hanmi Science CEO Lim Chong-yoon / Courtesy of Hanmi Pharmaceutical
Hanmi Pharmaceutical has consolidated its position as one of the leading drug makers in Korea, standing as the country's top pharmaceutical firm by market cap. However, growing risks from canceled license-out deals have overshadowed its pharmaceutical business recently, putting the group's leadership to the test.

Lim Chong-yoon, CEO of Hanmi Pharmaceutical Group's holding firm Hanmi Science, said the group's pharmaceutical portfolio is well-established globally, and so will not be swayed by those risks. At the same time, he said the group will not confine itself to being a drug maker and pursue the goal of becoming an "omnibus life care" provider to stay competitive in the market.

"Pharmaceuticals and biologics are among the most promising areas for Hanmi, but there are windows to look outside, and we plan to start a voyage to tap into unknown opportunities," Lim said during an interview with The Korea Times. "There is a curiosity basket filled with opportunities, and projects with schools, hospitals and therapeutic centers are where I would love to start."

Hanmi Science was established in 2010 as the group's holding firm. Its role is not limited to managing the group units and affiliates, but includes investments into R&D projects and new businesses in the healthcare sector.

One of the noteworthy projects by Lim is Coree Group, a group affiliate having units covering venture investments and new business incubation, such as digital medical services, nutrition consulting and a number of projects related to healthcare. As part of these, Coree launched biobank projects in Italy and China in 2018 along with local partners.

"We believe what is beyond pharmaceuticals is welfare," Lim said. "I have been thinking that we need a total reformation of the health industry chain from medicine to omnibus life care. And it is time for us to embrace creative destruction."

According to him, omnibus life care is providing full services to bring back health to a patient, meaning it includes not only the treatment of a disease through medication but also a study into the cause of the disease and ways to prevent it. For this, Hanmi Science takes care of the medical part and Coree is in charge of prevention and other services.

Along with Coree, Lim is expanding Hanmi's domain by opening up its businesses to outside partners.

On Dec. 9, he visited China and met iKang Healthcare Group Chairman Zhang Ligang. iKang Healthcare Group is a preventative healthcare provider based on a medical examination network. Reportedly, Lim and Zhang discussed the two sides' partnership for a digital examination system. In addition to iKang, Lim met with the leaders of three Chinese healthcare companies in December and discussed partnerships.

"Hanmi is one of the most active Korean drug makers to sign partnerships with global companies," Lim said. "However, the efforts were an outcome born out of desperation to overcome partnership rejections from global drug makers and the growing burden of its huge R&D investment."


Running into bumps

Lim's remark came amid growing risks in Hanmi's main business of drug manufacturing.

In January 2019, Eli Lilly returned the licensing rights for Bruton's tyrosine kinase inhibitor HM71224, which Hanmi Pharmaceutical licensed out in 2015 for $765 million. Six months later, Janssen handed back rights to HM12525A, an antidiabetic obesity treatment, which Hanmi also licensed out in 2015. The series of cancellations raised questions on Hanmi Pharmaceutical's pipeline.

Regarding this, Lim said failures and cancelations were common in the pharmaceutical business, and the company was not swayed by failure.

"Hanmi has already established itself, having over 400 drug licenses which use more than 90 percent of the manufacturing sites that the company owns," Lim said. "In China, we have about 50 drug licenses approved by the China Food & Drug Administration and three top prescribing drugs there."

Another risk which emerged recently is Efpeglenatide, a new diabetes drug candidate which Hanmi licensed out to Sanofi in 2015.

Efpeglenatide drew high expectation as it requires weekly injections, unlike most existing diabetes drugs which require daily ones.

However, new Sanofi CEO Paul Hudson said on Dec. 10 that the French pharma giant was stopping all research into diabetes and cardiovascular disease. Following the decision, Sanofi will finish the drug's phase three clinical trials but will not launch it and instead seek a partner to commercialize the drug.

Hanmi said the move was not related to the drug's efficacy and safety, and the details of the licensing agreement and the plan to file new drug applications in 2021 have not changed. However, this raised questions over Efpeglenatide's future in the market as well as affecting the stock prices of Hanmi Pharmaceutical and Hanmi Science.

"Sanofi, like many in this industry, is among the most strategic and dynamic firms when it comes to reform in my opinion, and it was a very bold decision by Sanofi that is in line with current changes in the treatment of chronic diseases," Lim said.

"For the market, it is a good time to find a partner since the technical strength of Efpeglenatide is still valid as seen in the current phase three clinical trials. It can serve many patients with the unique biological advantage of a prolonged-activity agonist molecule."

Unlike Hanmi, Sanofi terminated its diabetes drug partnership with Lexicon Pharmaceuticals in July as part of its farewell to diabetes drugs, despite paying $260 million to Lexicon.

As Lim said, a number of analysts said Sanofi's decision to finish Efpeglenatide's phase three trials means it highly evaluates the value of Hanmi's technology in developing the drug.

The technology, Lapscovery, is a platform technology that prolongs the duration of action of biologics, thus making it possible for once a week or monthly treatments. Hanmi has made sizable investments in recent years to produce biologics using Lapscovery.

"Lapscovery is effective as it can translate into many metabolic related treatments, and the world needs more advanced medicines using this technology to reduce patient inconvenience from outdated drug regimens."

Hanmi Pharmaceutical headquarters in Songpa-gu, Seoul / Courtesy of Hanmi Pharmaceutical
A Hanmi Pharmaceutical researcher tests a compound at the drug maker's research center in Hwaseong, Gyeonggi Province. Courtesy of Hanmi Pharmaceutical

Growing future experts

As part of his initiative to transform Hanmi group into a total healthcare service provider, Lim said the group believes in the power of education, so that more experts can expedite the growth of Hanmi and the country's pharmaceutical industry.

On Nov. 25, Hanmi Science signed an MOU with Pohang University of Science and Technology and agreed to carry out joint research and collaborative efforts to educate and train experts in biologics.

Following the MOU, the two sides will research the structure of cell membrane proteins by using light source facilities, cryogenic electron microscopy and various other tools to develop new drugs.

"The Korean biopharmaceutical industry is facing challenges and opportunities at the same time, and it can overcome those challenges through sharing its technology and opening up its businesses," Lim said. "We need better industrial motivation so as to produce more science lectures, projects, professors and students."


Emailnamhw@koreatimes.co.kr Article ListMore articles by this reporter
 
miguel
wooribank
LG
Top 10 Stories
1Guide to Chuseok celebrations across Korea Guide to Chuseok celebrations across Korea
2Chuseok exodus begins ahead of extended 6-day holiday Chuseok exodus begins ahead of extended 6-day holiday
3Korea sees record-low births in July Korea sees record-low births in July
4Hyundai E&C to build upmarket apartment complex in Seoul's Gwanak District Hyundai E&C to build upmarket apartment complex in Seoul's Gwanak District
5Political battle intensifies after court rejects Lee's arrest warrant Political battle intensifies after court rejects Lee's arrest warrant
6Korea on track to prove esports prowess at Asian Games Korea on track to prove esports prowess at Asian Games
7[INTERVIEW] Risk-averse culture is forcing daring creators to flee showbiz INTERVIEWRisk-averse culture is forcing daring creators to flee showbiz
8Lotte focuses on health care, mobility to spur growth Lotte focuses on health care, mobility to spur growth
9DMZ Open Int'l Music Festival to be held in Goyang in November DMZ Open Int'l Music Festival to be held in Goyang in November
10Two Koreas trade barbs over nuclear war Two Koreas trade barbs over nuclear war
Top 5 Entertainment News
1[INTERVIEW] 'Coexistence of different art hubs across Asia is necessary': Art Week Tokyo Director INTERVIEW'Coexistence of different art hubs across Asia is necessary': Art Week Tokyo Director
2Trailblazing nonagenarian artist honored for redefining Korean fiber art Trailblazing nonagenarian artist honored for redefining Korean fiber art
3[INTERVIEW] With '30 Days,' Kang Ha-neul finds new level of comfort in acting INTERVIEWWith '30 Days,' Kang Ha-neul finds new level of comfort in acting
4Rwandan artists bring diversity to Seoul's art scene Rwandan artists bring diversity to Seoul's art scene
5[INTERVIEW] ONEUS returns as 'mermaid prince' INTERVIEWONEUS returns as 'mermaid prince'
DARKROOM
  • Turkey-Syria earthquake

    Turkey-Syria earthquake

  • Nepal plane crash

    Nepal plane crash

  • Brazil capital uprising

    Brazil capital uprising

  • Happy New Year 2023

    Happy New Year 2023

  • World Cup 2022 Final - Argentina vs France

    World Cup 2022 Final - Argentina vs France

CEO & Publisher : Oh Young-jin
Digital News Email : webmaster@koreatimes.co.kr
Tel : 02-724-2114
Online newspaper registration No : 서울,아52844
Date of registration : 2020.02.05
Masthead : The Korea Times
Copyright © koreatimes.co.kr. All rights reserved.
  • About Us
  • Introduction
  • History
  • Contact Us
  • Products & Services
  • Subscribe
  • E-paper
  • RSS Service
  • Content Sales
  • Site Map
  • Policy
  • Code of Ethics
  • Ombudsman
  • Privacy Statement
  • Terms of Service
  • Copyright Policy
  • Family Site
  • Hankook Ilbo
  • Dongwha Group